Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection
about
Antifungal resistance in pathogenic fungiIn-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazoleDiscovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossingAspergillus susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapy.Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization.High resolution genotyping of clinical Aspergillus flavus isolates from India using microsatellitesSubcutaneous phaeohyphomycosis in transplant recipients: review of the literature and demonstration of in vitro synergy between antifungal agents.Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.Identification of novel genes conferring altered azole susceptibility in Aspergillus fumigatus.Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.Oxygen and an extracellular phase transition independently control central regulatory genes and conidiogenesis in Aspergillus fumigatusItraconazole--perspectives for the management of invasive aspergillosis.New and emerging antifungal agents: impact on respiratory infections.Differences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavus.Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.In vitro susceptibility testing in Aspergillus species: an update.Invasive aspergillosis: resistance to antifungal drugs.Azole resistance in Aspergillus: global status in Europe and Asia.Current status of antifungal resistance and its impact on clinical practice.Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus.Invasive fungal infection in patients with hematologic disorders in a Brazilian tertiary care hospital.Animal Models for Studying Triazole Resistance in Aspergillus fumigatus.Improved outcome of pulmonary aspergillosis in heart transplant recipients with early diagnosis and itraconazole treatment.Comparison of disk diffusion, E-test and broth microdilution test in determination of susceptibility of Aspergillus species to amphotericin B, itraconazole and voriconazole.Effect of medium composition on static and cidal activity of amphotericin B, itraconazole, voriconazole, posaconazole and terbinafine against Aspergillus fumigatus: a multicenter study.In-vitro activities of terbinafine, itraconazole and amphotericin B against Aspergillus and Cladosporium species.Susceptibility of sequential Fonsecaea pedrosoi isolates from chromoblastomycosis patients to antifungal agents.Aspergillus fumigatus harbouring the sole Y121F mutation shows decreased susceptibility to voriconazole but maintained susceptibility to itraconazole and posaconazole.In vitro activities of fluconazole, itraconazole and voriconazole against otomycotic fungal pathogens.The antifungal activity of 2,2'-diamino-4,4'-dithiazole derivatives is due to the possible inhibition of lanosterol-14-alpha-demethylase.The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis.Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India.Azole Resistance in Aspergillus fumigatus: Mechanisms, Route of Resistance Selection, and Clinical Implications
P2860
Q28208165-F42ECC1F-68B3-4CD5-B122-1F03CEB8E56CQ28377384-A77EE69A-BA3D-403A-B40A-9D6F0956F81AQ28485433-251E1BD1-1780-4887-B73B-EA28EE0AF4F1Q31004718-2DBD5016-E805-4B16-81FF-FB104CDDDBE8Q33689767-89910340-3127-4C32-881B-72C056C83853Q33802593-F8C6C5B8-39F5-4FF9-9CFD-63249B51806FQ33922036-27422C4E-90DB-4C06-89B3-71C9786EAF20Q34335230-BA109CBF-805F-4635-B18A-D457FB4EAA02Q34452089-16715DB6-C044-465B-9B3E-1C15AEEFF2A5Q34553509-9F9BDB1D-FB6B-4B45-908E-467663736624Q34990353-A10169CA-45A0-48E4-9197-0BFB7C38EAF0Q35105394-E34E63EA-6077-4305-9559-A7DB52EEAD81Q35627629-34B32CB6-9FB6-4543-A60A-2D116C0F3208Q37226618-702CCFB7-3524-4548-A727-1EB070C95DC9Q37688257-F1EBD2B8-F8E0-4729-B532-53E53EA42EB0Q37742178-6113E881-C8FA-4C08-B743-31F86B5C9BDAQ37983464-5E91A1E9-6B47-4D18-B49C-7CEBB3717B89Q38066613-8D7275FE-B3E2-4628-AB52-CECD587B29CBQ38205859-7F8AADAE-8CB2-4295-B522-EF7B29E02FECQ38711698-3A577FF5-0ACB-499C-9F75-6CF5DBF325BAQ38887496-9DF4438A-01BE-4533-B57D-DFF5A62BFCC5Q40045642-3A4C5705-BEB3-4B09-89F6-6214D3181847Q40616573-2DDACB02-3172-4A76-AA54-551B483A5558Q43815790-A0C23916-08B7-4DC6-BC96-7DDBC083E5D7Q44066015-C6A59AD7-EE74-42DD-A683-7A80681F749FQ44312882-0066B165-D5A2-4B46-B156-D0262A73E8F9Q44930550-4553005A-2B1B-4F4C-B0F8-F7E284A2E335Q45762787-09CB50A4-5559-4436-83FB-5E88D9995001Q46005292-A4284C68-9CBE-4F6E-AD73-F9799C49CDF3Q46545950-9382948D-EE17-4A45-96CE-4665BAAC38B8Q51191763-698C784A-7537-4FFE-B18F-049E53445F7FQ54342323-5EB92321-5276-42C9-8ECE-1010CA96EA17Q56993256-D898AFEF-EC82-4FED-B333-E2ECD9163741
P2860
Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection
description
im September 1997 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 September 1997
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 1997
@uk
name
Correlation between in-vitro s ...... spergillus fumigatus infection
@en
Correlation between in-vitro s ...... spergillus fumigatus infection
@nl
type
label
Correlation between in-vitro s ...... spergillus fumigatus infection
@en
Correlation between in-vitro s ...... spergillus fumigatus infection
@nl
prefLabel
Correlation between in-vitro s ...... spergillus fumigatus infection
@en
Correlation between in-vitro s ...... spergillus fumigatus infection
@nl
P2093
P356
P1476
Correlation between in-vitro s ...... spergillus fumigatus infection
@en
P2093
D W Warnock
E M Johnson
K L Oakley
S A Radford
P304
P356
10.1093/JAC/40.3.401
P407
P577
1997-09-01T00:00:00Z